ImmuDyne Announces Completion of Shapiro MD Formulation Work and Update on Launch
March 23 2017 - 8:30AM
ImmuDyne, Inc. (OTCQB:IMMD) (“ImmuDyne” or the “Company”), a leader
in the development and marketing of OTC healthcare products, today
announces that all formulation work has been completed on the
Shapiro MD product line. The first product run will occur
within the next 2-3 weeks and we anticipate a national product
launch no later than April 15, 2017.
In addition to the Shampoo and Conditioner, ImmuDyne also
formulated a once-daily leave in foam product that the Company
believes will be a strong addition to the product line.
Collectively, these products represent the most researched, all
natural and patented hair loss product line on the market.
“ImmuDyne and our Puerto Rico based subsidiary have been
receiving strong and almost daily interest from leading publishers
around the country that want to be the first to offer this
innovative product line,” stated Mark McLaughlin, Chief Executive
Officer of ImmuDyne. “I believe this high level of interest
from such respected parties speaks to the caliber of the science
behind the Shapiro MD products and the huge market need for a
differentiated product that works in the hair loss vertical.”
“We always knew that in the right hands, the Shapiro MD products
would be very successful,” said Dr. Steven Shapiro. "We’re
very excited for the product launch and are very optimistic that
the 10 years we invested in research and development to create
Shapiro MD will benefit people around the world that want an
all-natural solution for thicker and fuller hair.”
ImmuDyne will continue to keep shareholders and the public
apprised of all important milestones related to the launch of
Shapiro MD.
About lmmuDynelmmuDyne, Inc. (the "Company") is a health and
wellness company which develops, manufactures, markets, and sells
innovative lifestyle products. The Company's lead products contain
its proprietary yeast beta glucans that have been shown through
testing and analysis to support the immune system. The Company's
products include once a day oral intake capsules as well as topical
serums and creams for skin application. lmmuDyne also has developed
a proprietary natural delivery technology for potential new market
opportunities. All of lmmuDyne's intellectual property is protected
by patents and/or trade secrets. Additional information can be
found on the web at www.immudyne.com.
Forward-Looking StatementsCautionary language regarding
Forward-Looking Statements Safe Harbor Act Disclaimer: Forward
looking statements in this release are made pursuant to the Safe
Harbor Provisions of the Private Securities Litigation Reform Act
of 1995. Certain statements in this press release, including
projections with respect to lmmuDyne's results of operations, may
contain words such as "anticipates," "believes," "could,"
"estimates," "expects," "intends," "may," "projects,"
"plans," "targets" and other similar language and are
considered forward-looking statements. These statements are based
on management's current expectations, estimates, and forecasts.
These forward-looking statements are subject to important
assumptions, risks and uncertainties, which are difficult to
predict and therefore the actual results may be materially
different from those discussed.
Contact:
ImmuDyne, Inc.
Mark McLaughlin: +1-914-714-8901